Education
About Us
Working with TipRanks
Follow Us
Shanghai Haohai Biological Technology Co., Ltd. Class H (HK:6826)
:6826
6826 Stock Chart & Stats
HK$26.90
-HK$0.40(-1.57%)
At close: 4:00 PM EST
HK$26.90
-HK$0.40(-1.57%)
Day’s Range― - ―
52-Week RangeHK$21.70 - HK$34.35
Previous CloseN/A
Volume220.22K
Average Volume (3M)260.46K
Market Cap
HK$11.67B
Enterprise ValueHK$4.03B
Total Cash (Recent Filing)HK$2.66B
Total Debt (Recent Filing)HK$439.76M
Price to Earnings (P/E)15.1
Beta0.88
Next Earnings
Mar 23, 2026EPS EstimateN/A
Last Dividend Ex-Date
Sep 05, 2025Dividend Yield4.05%
Share Statistics
EPS (TTM)0.45
Shares Outstanding38,529,240
10 Day Avg. Volume235,438
30 Day Avg. Volume260,460
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)1.05
Price to Sales (P/S)2.18
P/FCF Ratio20.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Shanghai Haohai Biological Technology Co., Ltd. Class H News
6826 FAQ
What was Shanghai Haohai Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Haohai Biological Technology Co., Ltd. Class H lowest stock price was HK$21.70 and its highest was HK$34.35 in the past 12 months.
What is Shanghai Haohai Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s market cap is HK$11.67B.
When is Shanghai Haohai Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Mar 23, 2026 which is in 141 days.
How were Shanghai Haohai Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Haohai Biological Technology Co., Ltd. Class H released its earnings results on Oct 24, 2025. The company reported HK$0.448 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.448.
Is Shanghai Haohai Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Haohai Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Haohai Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Haohai Biological Technology Co., Ltd. Class H pays a Quarterly dividend of HK$0.438 which represents an annual dividend yield of 4.05%. See more information on Shanghai Haohai Biological Technology Co., Ltd. Class H dividends here
What is Shanghai Haohai Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Haohai Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Haohai Biological Technology Co., Ltd. Class H have?
Shanghai Haohai Biological Technology Co., Ltd. Class H has 38,529,240 shares outstanding.
What happened to Shanghai Haohai Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Haohai Biological Technology Co., Ltd. Class H reported an EPS of HK$0.448 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.325%.
Which hedge fund is a major shareholder of Shanghai Haohai Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.97%
12-Months-Change
Fundamentals
Return on Equity
6.69%
Trailing 12-Months
Asset Growth
-3.01%
Trailing 12-Months
Company Description
Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) is a leading biotechnology company based in China, specializing in the research, development, production, and sale of biological and pharmaceutical products. The company's core products include ophthalmic products, medical aesthetics, orthopedic products, and anti-adhesion and hemostasis products. With a robust focus on innovation, Haohai leverages advanced biological technology to deliver high-quality medical solutions across its key sectors.
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) Earnings & Revenues
Technical Analysis
Ascletis Pharma, Inc.
―
Lepu Biopharma Co. Ltd. Class H
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Options Prices
Currently, No data available
---